National and Local Joint Engineering Laboratory for Key Technologies in Medical Synthetic Biology Applications
The laboratory was established in June 2015, with Professor Zhimin Cai, a Fellow of the American Institute for Medical and Biological Engineering and chief scientist of China's 973 Programat the Second People's Hospital of Shenzhen, serving as the chairman of the Academic Committee. The main research directions of the laboratory focus on malignant tumors, exploring bacterial genetic engineering identification technology, T-cell immunotherapy technology, antigen-conjugated immune adjuvant technology, and humanized Fzd7 monoclonal antibody research. The laboratory aims to utilize synthetic biology techniques to overcome bladder cancer and provide new ideas for cancer treatment. The research and development area of the laboratory covers 3,500 square meters, with equipment valued at 45 million yuan. The laboratory actively recruits high-level talents from both domestic and international sources, including one academician from the three major academies in the United States, professors from the University of California, Baylor College of Medicine, and the University of Hong Kong. The team includes 14 Ph.D. supervisors and 11 returnees from overseas studies. The laboratory has published a total of 237 SCI papers, including 21 SCI papers with an impact factor over 10; it holds 17 authorized invention patents and has received multiple scientific and technological awards at various levels.
National and Local Joint Engineering Laboratory for Key Technologies in Tumor Genomics Clinical Applications
Against the backdrop of revolutionary breakthroughs brought by the completion of the Human Genome Project and the application of next-generation sequencing technology in the entire major disease research field, the Second People's Hospital of Shenzhen established the Shenzhen Tumor Genomics Clinical Application Engineering Laboratory in 2011, which was approved as a National and Local Joint Engineering Laboratory in 2012. The laboratory is led by Professor Zhimin Cai, an expert with special government allowances from the State Council and chief scientist of the 973 Program. The laboratory mainly conducts clinically oriented translational research on targeted therapies. After its establishment, the laboratory promoted the hospital to lead and unite dozens of hospitals domestically and internationally to initiate the "Urogenital System Tumor Genomics Project," aiming to comprehensively understand the mechanisms of occurrence and development of urogenital system diseases. The laboratory has published 250 SCI-indexed papers, including 21 with impact factors above 10; it has earned multiple national scientific and technological awards and holds 17 invention patents.
